Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial.

By Michael Miller, C. Cannon, S. Murphy, J. Qin, K. Ray, E. Braunwald. Journal of the American College of Cardiology, 2008

624 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, Surgery

View Paper: https://www.semanticscholar.org/paper/e4a465c4bf5d06da92dad85b0389b39a7eacbd2b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Marja-Riitta Taskinen
2. Børge G. Nordestgaard

In Endocrinology, Diabetes and Metabolism

1. Børge G. Nordestgaard
2. Jan Boren
3. A. Tybjærg-Hansen
4. Marja-Riitta Taskinen
5. L. Tokgözoğlu
6. I. Graham

In Surgery

1. Jan Boren
2. A. Tybjærg-Hansen
3. Børge G. Nordestgaard
4. Marja-Riitta Taskinen
5. L. Tokgözoğlu
6. I. Graham

Citations in the corpus

• Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management (2011, background): “levels and changes from baseline levels for triglycerides and reduction in CV risk,(103) data from more recent trials are indicative of association.(11,104,105) In the PROVE IT-TIMI 22 trial, on-treatment”